PP
PGNX

Paloma Partners’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Paloma Partners’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-34,655
Closed -$176K – 2373
2019
Q4 		$176K Buy
+34,655
New +$183K ﹤0.01% 1995
2017
Q1 		– Sell
-13,992
Closed -$121K – 2354
2016
Q4 		$121K Buy
+13,992
New +$103K ﹤0.01% 1896
2015
Q2 		– Sell
-16,100
Closed -$96K – 2008
2015
Q1 		$96K Sell
16,100
-16,713
-51% -$105K ﹤0.01% 1121
2014
Q4 		$248K Buy
+32,813
New +$196K 0.01% 937

Other funds holding PGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Paloma Partners's PGNX Position: Q1 2020 in Review

Paloma Partners sold out of Progenics Pharmaceuticals Inc (PGNX) in Q1 2020, closing a stake of 34,655 shares — an estimated $176K sold.

Paloma Partners first reported a position in PGNX in Q4 2014 and held it in 4 quarters. The position peaked at $248K in Q4 2014. 129 funds tracked by Wall St. Rank hold PGNX as of Q1 2020.

  • Paloma Partners reported no remaining Progenics Pharmaceuticals Inc position as of Q1 2020 after selling out during the quarter.
  • Paloma Partners sold 34,655 Progenics Pharmaceuticals Inc shares in Q1 2020, an estimated $176K.
  • Paloma Partners first reported a position in Progenics Pharmaceuticals Inc in Q4 2014 and held it in 4 quarters.
  • Paloma Partners's Progenics Pharmaceuticals Inc position peaked at $248K in Q4 2014.
  • 129 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q1 2020.

Based on Paloma Partners's 13F filing for Q1 2020, filed 15 May 2020.